Eric Greenbaum is the Chief Science Officer of Vireo Health and has an impressive combination of scientific and legal expertise. Eric began his career working on stem cell and gene therapies for neurometabolic diseases. He went on to explore the role of protein folding in neurodegenerative diseases and led the team that performed the first biochemical characterization of the newly discovered E46K mutation responsible for a form of early onset Parkinson‘s Disease. After leaving academic science, Eric ran a boutique IP law firm where he crafted global patent strategies for biotech and pharmaceutical inventions. Since joining Vireo Health, Eric has been instrumental in developing our IP portfolio and driving our R&D efforts. Eric received a bachelors of science from Emory University in neuroscience; a masters of science from the University of Pennsylvania in pharmacology; and a JD from St. John’s University.